Ascletis Pharma Inc (1672) H1 2025 earnings summary

Executive summary

• Total income rose 111.4% YoY to RMB103.6m and net loss narrowed 32.5% to RMB88.0m, despite a 10.9% increase in R&D spending.

• Pipeline advances spanned obesity, immunology and acne; RMB1,827.9m in cash and other liquid resources is expected to fund R&D and operations through 2029.

Financial highlights

• Total income was RMB103.6m, comprising RMB1.1m revenue and RMB102.5m other income and gains.

• Net loss was RMB88.0m versus RMB130.3m in H1 2024; basic and diluted loss per share improved to RMB0.0914 from RMB0.1282.

• R&D costs rose 10.9% to RMB146.8m, mainly reflecting greater investment in metabolic disease programs; administrative expenses increased 4.7% to RMB43.3m.

• Other income and gains rose to RMB102.5m from RMB49.0m, including RMB39.2m of net FVPL gains and RMB34.2m in government grants.

• Operating cash outflow was RMB173.0m; investing activities generated RMB904.6m, mainly from lower time deposits with original maturities over three months.

Outlook and guidance

• ASC30 oral obesity Phase IIa topline results are expected in Q4 2025; monthly-or-less-frequent injection Phase IIa topline results are expected in Q1 2026.

• ASC47 plus semaglutide and ASC50 Phase I SAD topline data are expected in 2025; ASC30 injection Phase IIa enrollment is targeted for completion in 2025.

• Plans include advancing discovery through AISBDD and ULAP and seeking licensing partners for multiple assets, including denifanstat in acne; ASC61 is being considered for licensing out.

• Cash, deposits, transferable certificates, structured deposits, wealth management products and cash in transit totaled RMB1,827.9m at June 30, 2025, expected to fund operations and R&D through 2029.